Recorded fact · drug.label_indication
drug.label_indication for diroximel-fumarate|multiple-sclerosis
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact daa1cb01 resolves to.
The record
| Fact id | daa1cb0165a0aeb53b247f33 |
|---|---|
| Entity | drug: diroximel-fumarate|multiple-sclerosis |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20250529 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 75c538ee2982763e4162ab8982207a2bfb073037dba50ec38332a1174b5e8c4a.
The value
{
"ingredient": "Diroximel Fumarate",
"conditionId": "multiple-sclerosis",
"conditionName": "Multiple Sclerosis",
"matchedAlias": "multiple sclerosis",
"context": "indication",
"brand": "Vumerity",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "2d74414f-6b83-4ea2-9a95-3cecabbce774",
"labelEffectiveTime": "20250529",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: e8b98bd8f12c8c4eeef488ea334da6fa0d8a753c42d302472d26ff8f687da3c4.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.